Physician profile
Jay Kuchera
NPI 1013974450
$7,842.33
in general payments reported to CMS, 2019-2025
31 companies · $338 in 2025
The $338 reported for 2025 was more than what 88% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,147 · 2020: $936 · 2021: $439 · 2022: $279 · 2023: $554 · 2024: $150 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,042.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,041.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $5,418.45 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $715.34 | 2019-2025 | Belbuca, Xtampza |
| Abbvie INC. | $197.63 | 2022-2024 | |
| Orexo US, INC. | $154.96 | 2019-2025 | Zubsolv |
| Si-Bone, INC. | $154.19 | 2025 | |
| Almatica Pharma LLC | $141.34 | 2021-2023 | Gralise |
| Forte Bio-Pharma LLC | $133.36 | 2023 | Prolate, Nalocet |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.32 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $108.67 | 2019-2020 | |
| Daiichi Sankyo INC. | $97.95 | 2019 | |
| Pfizer INC. | $59.74 | 2019 | |
| Hikma Pharmaceuticals USA | $57.45 | 2021-2022 | |
| Grt US Holding, INC. | $56.31 | 2021 | |
| Spr Therapeutics, INC | $44.86 | 2023-2025 | Sprint Pns System |
| Kowa Pharmaceuticals America, INC. | $44.59 | 2023 | Seglentis |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valinor Pharma, LLC | $42.33 | 2023 | Movantik |
| Arbor Pharmaceuticals, INC. | $25.73 | 2019-2021 | |
| Abbott Laboratories | $25.40 | 2025 | Eterna |
| Mdd US Operations, LLC | $23.00 | 2019 | |
| Kaleo, INC. | $22.86 | 2019 | |
| Ibsa Pharma INC. | $22.58 | 2022 | |
| Biotronik Nro, INC. | $22.55 | 2025 | Prospera |
| Averitas Pharma INC. | $21.21 | 2024 | Qutenza |
| Vertex Pharmaceuticals Incorporated | $19.56 | 2025 | |
| Boston Scientific Corporation | $18.84 | 2024 | |
| Fidia Pharma USA INC. | $17.52 | 2019 | |
| Redhill Biopharma INC. | $15.84 | 2021 | |
| Horizon Therapeutics Plc | $15.14 | 2022 | |
| Novo Nordisk INC | $13.65 | 2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $13.56 | 2022 | |
| Allergan, INC. | $13.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Kuchera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.